Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201 Meeting Abstract
| Authors: | Mora, J.; Bear, M.; Chan, G.; Morgenstern, D. A.; Nysom, K.; Tornøe, K.; Losic, N.; Kushner, B. |
| Abstract Title: | Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma (HR NB): Updated efficacy and safety data from the international, multicenter phase II trial 201 |
| Meeting Title: | ESMO Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2021 Sep 16-21 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-09-01 |
| Start Page: | S833 |
| Language: | English |
| ACCESSION: | WOS:000700527701426 |
| DOI: | 10.1016/j.annonc.2021.08.1348 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract #963MO -- Source: Wos |
